Conjugated To A Cytotoxic Agent, Drug, Or Other Biologically-active Substance Patents (Class 530/391.7)
-
Publication number: 20140286859Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.Type: ApplicationFiled: September 10, 2012Publication date: September 25, 2014Applicants: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Publication number: 20140287464Abstract: The invention provides orthogonal translation systems for the production of polypeptides comprising unnatural amino acids in methylotrophic yeast such as Pichia pastoris. Methods for producing polypeptides comprising unnatural amino acids in methylotrophic yeast such as Pichia pastoris are also provided.Type: ApplicationFiled: January 27, 2014Publication date: September 25, 2014Inventors: Travis Young, Peter G. Schultz
-
Publication number: 20140286963Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.Type: ApplicationFiled: May 30, 2014Publication date: September 25, 2014Applicant: GENENTECH, INC.Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
-
Publication number: 20140286862Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: ApplicationFiled: October 26, 2012Publication date: September 25, 2014Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Publication number: 20140287446Abstract: A method of producing an antibody comprises immunizing a mammal with an amine-derivative of acetylamantadine, immunizing the mammal with acetylamantadine, and producing the antibody from the mammal. The antibody recognizes acetylamantadine but does not recognize amantadine.Type: ApplicationFiled: May 11, 2012Publication date: September 25, 2014Applicant: BioMark Technologies Inc.Inventors: Brian Cheng, Rashid Bux, Gregorio Aversa, Bram Ramjiawan, Daniel Sitar
-
Publication number: 20140286968Abstract: The invention provides methods for obtaining compositions having antibody drug conjugates (ADCs) with specified drug to antibody ratios (DARs). Included in the invention is a method for purifying an ADC mixture having ADCs with a drug loaded species of 6 or more by contacting the mixture with a hydrophobic resin such that a composition comprising less than 15% of the 6 or more drug loaded species is obtained. The invention also provides a composition wherein 70% or more of the ADCs present have a drug loaded species of 4 or less, wherein the ADC comprises an anti-EGFR antibody and an auristatin.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Inventors: Marvin Robert Leanna, Calvin Lawrence Becker
-
Patent number: 8841425Abstract: New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the ?-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.Type: GrantFiled: March 9, 2011Date of Patent: September 23, 2014Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Wayne C. Widdison
-
Publication number: 20140271457Abstract: Engineered multivalent and multispecific binding proteins that bind TNF? and IL-13, TNF? and PGE2, or TNF? and NGF are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: ABBVIE INC.Inventors: Tariq Ghayur, Carrie Goodreau
-
Publication number: 20140271676Abstract: Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Clark PAN, Huawei QIU
-
Publication number: 20140275487Abstract: The present invention relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present invention relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present invention can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: ApplicationFiled: June 21, 2012Publication date: September 18, 2014Inventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Søren Rasmussen, Sébastien Granier, Roger K. Sunahara
-
Publication number: 20140271640Abstract: The present disclosure provides complexes comprising an FGF-10 portion and a heterologous protein or peptide, as well as methods of using such complexes.Type: ApplicationFiled: December 6, 2013Publication date: September 18, 2014Applicant: PERMEON BIOLOGICS, INC.Inventors: Katherine S. Bowdish, Erik M. Vogan, John F. Ross, Ann Dewitt
-
Publication number: 20140271458Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: AbbVie Inc.Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
-
Publication number: 20140271462Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.Type: ApplicationFiled: March 10, 2014Publication date: September 18, 2014Applicant: IMAGINAB, INC.Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
-
Publication number: 20140271685Abstract: In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: BIN LIU
-
Patent number: 8834883Abstract: Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.Type: GrantFiled: June 14, 2011Date of Patent: September 16, 2014Assignee: Vaccinex, Inc.Inventors: Leslie A. Croy, Mark J. Paris, Ernest S. Smith
-
Patent number: 8835611Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: February 13, 2012Date of Patent: September 16, 2014Assignee: Wyeth Holdings LLCInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
-
Publication number: 20140255410Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: ApplicationFiled: December 11, 2012Publication date: September 11, 2014Applicant: ABBVIE INC.Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Publication number: 20140256916Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.Type: ApplicationFiled: February 5, 2014Publication date: September 11, 2014Inventors: Jochen Kruip, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken
-
Publication number: 20140255389Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: May 29, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH- GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
-
Publication number: 20140255411Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: March 18, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Zurit LEVINE, Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi ROSENBERG, Cynthia KOIFMAN, Dalit LANDESMAN-MILO, Eve MONTIA, Galit ROTMAN, Liat DASSA, Marina BUBIS, Merav BEIMAN, Ofer LEVY, Sergey NEMZER, Shira WALACH, Shirley SAMEACH- GREENWALD, Tania PERGAM, Yaron KINAR
-
Publication number: 20140256583Abstract: The invention relates to human endogenous retrovirus env (HERV-WL) polypeptides, nucleotide sequences, HERV-WL antibodies, methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicant: Rutgers, The State University of New JerseyInventors: Vincent K. Tsiagbe, Yu Li
-
Patent number: 8828399Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.Type: GrantFiled: March 1, 2012Date of Patent: September 9, 2014Assignee: The Trustees of Princeton UniversityInventors: Thomas Shenk, Dai Wang
-
Patent number: 8828389Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: December 7, 2011Date of Patent: September 9, 2014Assignee: Amorfix Life Sciences Ltd.Inventor: Neil Cashman
-
Publication number: 20140248283Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: ALPER BIOTECH, LLCInventor: Özge Alper
-
Publication number: 20140248282Abstract: As a result of producing anti-DDR1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of DDR1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of DDR1 in cells, and (vi) an activity to decrease the expression level of TGF-? in cells.Type: ApplicationFiled: August 23, 2012Publication date: September 4, 2014Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Mei Ono, Yuji Sano, Tsukasa Suzuki
-
Patent number: 8822652Abstract: Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells.Type: GrantFiled: December 8, 2010Date of Patent: September 2, 2014Assignee: Institut National de la Sante et de la Recherche MedicaleInventors: Michel Pierres, Eric Vivier, Myriam Baratin
-
Patent number: 8821880Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.Type: GrantFiled: September 9, 2009Date of Patent: September 2, 2014Assignee: China Synthetic Rubber CorporationInventors: Kuo-Jang Kao, Andrew T. Huang
-
Patent number: 8822645Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: July 8, 2009Date of Patent: September 2, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Jijie Gu, Peter C. Isakson
-
Publication number: 20140242075Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.Type: ApplicationFiled: July 6, 2012Publication date: August 28, 2014Applicant: GENMAB B.V.Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
-
Publication number: 20140235835Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: ApplicationFiled: March 7, 2014Publication date: August 21, 2014Applicant: WYETH HOLDINGS LLCInventors: ARTHUR KUNZ, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Publication number: 20140234209Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicant: Immunomedics, Inc.Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20140234903Abstract: A novel gene cluster encoding polypeptides involved in the generation of bio synthetically unique peptide-based compounds is described. In addition, new methods for biosynthetic engineering and production of modified peptides and proteins are disclosed. Furthermore, new tools for identification of homologue polypeptides and precursor peptides in other species are provided. In addition, peptide-based compounds and fusions of these compounds with functional moieties for treatment of disorders such as tumors are disclosed.Type: ApplicationFiled: September 5, 2012Publication date: August 21, 2014Applicant: ETH ZURICHInventors: Jorn Piel, Cristian Gurgui, Michael Francis Freeman, Agustinus Robert Uria, Maximilian Johannes Helf
-
Publication number: 20140234345Abstract: The present application is directed to covalent conjugates between an isocarbostyril alkaloid and a lipophilic biomolecule, to pharmaceutical compositions comprising the conjugates and to therapeutic uses thereof, in particular for treating cancer.Type: ApplicationFiled: July 11, 2012Publication date: August 21, 2014Applicant: BIOLYSE PHARMA CORPORATIONInventors: Claude Mercure, Rajashree Sathyamurthy
-
Publication number: 20140234218Abstract: The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (VL) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.Type: ApplicationFiled: October 15, 2013Publication date: August 21, 2014Applicant: GARVAN INSTITUTE OF MEDICAL RESEARCHInventors: Daniel Christ, Kip Dudgeon, Romain Rouet
-
Patent number: 8808702Abstract: Compounds useful as antiproliferative agents according to formula (I): wherein Ar1, Ar2, Ar3, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.Type: GrantFiled: December 12, 2007Date of Patent: August 19, 2014Assignee: Temple University-of the Commonwealth System of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy
-
Patent number: 8809507Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: GrantFiled: December 7, 2009Date of Patent: August 19, 2014Inventor: Vuong Trieu
-
Publication number: 20140227294Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).Type: ApplicationFiled: December 23, 2013Publication date: August 14, 2014Applicant: ABBVIE INC.Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. DiGiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
-
Publication number: 20140227344Abstract: The présent invention relates to cell-penetrating peptides characterized in that it comprises an amino acid séquence selected in the group consisting of X1LX2RALWX9LX3X9X4LWX9LX5X6X7X8, X1LX2LARWX9LX3X9X4LWX9LX5X6X7X8 and X1LX2ARLWX9LX3X9X4LWX9LX5X6X7X8, wherein X1 is beta-A or S, X2 is F or W, X3 is L, W, C or I, X4 is S, A, N or T, Xs is L or W, X6 is W or R, X7 is K or R, X8 is A or none, and X9 is R or S. Thèse peptides exhibit high efficiency, low toxicity and a natural tropism for lung tissues, and can be used either in simple complex with the cargo to be vectorised, or in nanoparticles comprising two layers of cell-pentrating peptides around the cargo.Type: ApplicationFiled: April 4, 2012Publication date: August 14, 2014Applicants: UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Gilles Divita, Karidia Konate, May Catherine Morris, Sebastien Deshayes
-
Publication number: 20140227268Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.Type: ApplicationFiled: April 16, 2014Publication date: August 14, 2014Applicant: Baylor Research InstituteInventors: Jacques F. Banchereau, Sangkon Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
-
Publication number: 20140227291Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.Type: ApplicationFiled: August 12, 2011Publication date: August 14, 2014Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giasi, Ulrich Ebert, Chung-Ming Hsieh
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Patent number: 8802826Abstract: Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: November 24, 2010Date of Patent: August 12, 2014Assignees: Alethia Biotherapeutics Inc., National Research Council of CanadaInventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
-
Publication number: 20140219912Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: December 19, 2013Publication date: August 7, 2014Applicant: AbbVie, Inc.Inventors: Tariq GHAYUR, Junjian LIU, Peter C. ISAKSON
-
Publication number: 20140219956Abstract: Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease.Type: ApplicationFiled: February 7, 2014Publication date: August 7, 2014Applicant: Immunomedics, Inc.Inventors: Serengulam V. Govindan, William J. McBride, Nalini Sathyanarayan, Christine Mazza-Ferreira, David M. Goldenberg
-
Publication number: 20140219913Abstract: Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: December 27, 2013Publication date: August 7, 2014Applicant: AbbVie, Inc.Inventors: Tariq Ghayur, Philip Bardwell
-
Publication number: 20140220045Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: ApplicationFiled: February 7, 2014Publication date: August 7, 2014Applicant: NANOONCOLOGY, INC.Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
-
Publication number: 20140221283Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: August 7, 2014Applicant: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, David L. Smiley
-
Publication number: 20140220031Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.Type: ApplicationFiled: December 19, 2013Publication date: August 7, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J.M. Hanf
-
Publication number: 20140212432Abstract: The present disclosure relates to antibodies specific for urokinase-type plasminogen activator (uPA). According to certain embodiments, the anti-uPA antibody specifically binds to the active form of uPA. In certain aspects, the anti-uPA antibody that specifically binds to active uPA binds specifically to the active form of human uPA (e.g., the antibody does not cross-react with active forms of uPA from non-human organisms). In certain aspects, an anti-uPA antibody of the present disclosure competes for specific binding to uPA with plasminogen activator inhibitor type 1 (PAI-1), where binding of the antibody to uPA results in internalization of a complex that includes the antibody, uPA, and urokinase-type plasminogen activator receptor (uPAR). Also provided are antibodies that specifically bind to uPA and compete for binding to uPA with a synthetic ligand of uPA. The disclosure also provides anti-uPA antibody conjugates and compositions (e.g.Type: ApplicationFiled: January 23, 2014Publication date: July 31, 2014Inventors: Natalia Sevillano, Aaron M. Lebeau, Daniel Robert Hostetter, Charles S. Craik
-
Publication number: 20140212440Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.Type: ApplicationFiled: June 15, 2012Publication date: July 31, 2014Applicant: HANMI SCIENCE CO., LTDInventors: Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon